Merck, Schering-Plough report strong second-quarter sales

Share this article:

Merck and Schering-Plough each reported strong second-quarter sales results today.

Merck's second-quarter highlights included:
*Growth in global sales for asthma and allergic rhinitis treatment Singulair by 15% to $1.1 billion. 
*Global sales growth of antihypertensive medicines Cozaar and Hyzaar of 8% to $847 million.
*Global sales of $358 million for cervical cancer vaccine Gardasil.
*Global sales of $144 million for Januvia, Merck's first-in-class treatment for Type 2 diabetes.

Meanwhile, Schering-Plough's second-quarter sales increased by 13%, to almost $3.2 billion, as the company continues to benefit from a leadership turnaround under Fred Hassan.

Schering-Plough's second-quarter highlights included:
*A global sales increase for arthritis drug Remicade of 28% to $394 million.
*A global sales increase for allergy treatment Nasonex of 22% to $295 million.
*A global sales increase for seasonal allergic rhinitis drug Clarinex to $250 million from $226 million.
*International sales growth for Temodar, a treatment for certain types of brain tumors of 26% to $216 million.
*An increase in sales of Pegintron for hepatitis C of 3% to $234 million, due to higher sales in Latin America and Europe, and tempered by lower sales in the United States and Japan.

Merck and Schering-Plough's quarterly performance was helped by the joint venture between the companies to market cholesterol drugs Vytorin and Zetia. Sales of the drugs rose $1.3 billion in the quarter, up 30% from a year earlier.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.